Free Trial

Evaxion A/S (EVAX) Competitors

Evaxion A/S logo
$3.11 -0.10 (-3.12%)
Closing price 03:55 PM Eastern
Extended Trading
$3.11 0.00 (0.00%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVAX vs. AIMD, LEXX, BLRX, ATHA, ADAP, EDSA, IMNN, MTVA, NEUP, and PRPH

Should you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Ainos (AIMD), Lexaria Bioscience (LEXX), BioLineRx (BLRX), Athira Pharma (ATHA), Adaptimmune Therapeutics (ADAP), Edesa Biotech (EDSA), Imunon (IMNN), MetaVia (MTVA), Neuphoria Therapeutics (NEUP), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

Evaxion A/S vs. Its Competitors

Evaxion A/S (NASDAQ:EVAX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Evaxion A/S has higher revenue and earnings than Ainos. Evaxion A/S is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion A/S$3.18M1.37-$10.57M-$1.32-2.36
Ainos$20K957.63-$14.86M-$4.99-0.82

Evaxion A/S currently has a consensus target price of $10.00, suggesting a potential upside of 221.54%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Ainos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ainos
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ainos has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Ainos' return on equity of -108.25% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion A/S-316.03% -319.52% -63.56%
Ainos N/A -108.25%-56.94%

11.0% of Evaxion A/S shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 10.4% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evaxion A/S had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Evaxion A/S and 1 mentions for Ainos. Evaxion A/S's average media sentiment score of 0.67 beat Ainos' score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media.

Company Overall Sentiment
Evaxion A/S Positive
Ainos Neutral

Evaxion A/S has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.

Summary

Evaxion A/S beats Ainos on 10 of the 16 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$4.36M$2.07B$5.74B$9.77B
Dividend YieldN/AN/A4.40%4.08%
P/E Ratio-2.3637.6230.4126.04
Price / Sales1.379.64428.97104.72
Price / CashN/A53.5525.7828.79
Price / Book-2.6410.869.706.08
Net Income-$10.57M-$63.67M$3.27B$265.64M
7 Day Performance2.30%4.02%3.94%3.11%
1 Month Performance14.34%1.05%3.81%0.39%
1 Year Performance-79.81%27.02%31.26%18.52%

Evaxion A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion A/S
1.9424 of 5 stars
$3.11
-3.1%
$10.00
+221.5%
-79.6%$4.36M$3.18M-2.3660
AIMD
Ainos
0.6037 of 5 stars
$3.35
-3.2%
N/A+20.0%$16.12M$20K-0.6740
LEXX
Lexaria Bioscience
3.3381 of 5 stars
$0.84
+2.1%
$4.00
+378.2%
-65.3%$16.03M$460K-1.257Gap Up
BLRX
BioLineRx
3.3813 of 5 stars
$3.83
+3.2%
$26.00
+578.9%
-86.9%$15.81M$28.94M-0.4440
ATHA
Athira Pharma
3.0756 of 5 stars
$0.39
-1.9%
$0.50
+27.3%
-87.7%$15.80MN/A-0.2540Positive News
Gap Down
ADAP
Adaptimmune Therapeutics
2.0539 of 5 stars
$0.07
+17.6%
$1.35
+1,831.0%
-95.0%$15.77M$65.09M-0.11490High Trading Volume
EDSA
Edesa Biotech
1.5265 of 5 stars
$2.31
+3.4%
$5.00
+116.9%
-45.6%$15.73MN/A-1.7520Gap Up
High Trading Volume
IMNN
Imunon
1.2434 of 5 stars
$6.48
+1.3%
$232.50
+3,488.0%
-66.4%$15.62M$500K-0.5030
MTVA
MetaVia
2.4808 of 5 stars
$0.65
+1.7%
$7.50
+1,052.8%
N/A$15.49MN/A0.008
NEUP
Neuphoria Therapeutics
1.1701 of 5 stars
$7.79
-3.8%
$21.00
+169.6%
N/A$15.23M$10K0.00N/AAnalyst Forecast
PRPH
ProPhase Labs
1.2395 of 5 stars
$0.33
-4.4%
N/A-87.5%$14.51M$6.77M-0.27130

Related Companies and Tools


This page (NASDAQ:EVAX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners